Your browser doesn't support javascript.
loading
Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma.
Du, Chunxia; da Silva, Annacarolina; Morales-Oyarvide, Vicente; Dias Costa, Andressa; Kozak, Margaret M; Dunne, Richard F; Rubinson, Douglas A; Perez, Kimberly; Masugi, Yohei; Hamada, Tsuyoshi; Brais, Lauren K; Yuan, Chen; Babic, Ana; Ducar, Matthew D; Thorner, Aaron R; Aguirre, Andrew; Kulke, Matthew H; Ng, Kimmie; Clancy, Thomas E; Findeis-Hosey, Jennifer J; Chang, Daniel T; Hornick, Jason L; Fuchs, Charles S; Ogino, Shuji; Koong, Albert C; Hezel, Aram F; Wolpin, Brian M; Nowak, Jonathan A.
Afiliação
  • Du C; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • da Silva A; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Morales-Oyarvide V; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Dias Costa A; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Kozak MM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Dunne RF; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Rubinson DA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Perez K; Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California.
  • Masugi Y; Division of Hematology and Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
  • Hamada T; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Brais LK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Yuan C; Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
  • Babic A; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ducar MD; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Thorner AR; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Aguirre A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Kulke MH; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Ng K; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Clancy TE; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Findeis-Hosey JJ; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Chang DT; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Hornick JL; Section of Hematology/Oncology, Boston University and Boston Medical Center, Boston, Massachusetts.
  • Fuchs CS; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Ogino S; Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Koong AC; Department of Pathology, University of Rochester Medical Center, Rochester, New York.
  • Hezel AF; Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California.
  • Wolpin BM; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Nowak JA; Yale Cancer Center, Smilow Cancer Hospital and Yale School of Medicine, New Haven, Connecticut.
Cancer Epidemiol Biomarkers Prev ; 29(8): 1586-1595, 2020 08.
Article em En | MEDLINE | ID: mdl-32467349
BACKGROUND: Insulin-like growth factor-1 receptor (IGF1R) signaling is important in pancreatic ductal adenocarcinoma (PDAC) biology, but little is known regarding IGF1R expression and patient characteristics and outcomes. METHODS: In 365 patients with resected PDAC, we evaluated IGF1R protein expression using IHC on whole-slide sections and IGF1R genomic status using next-generation sequencing. Associations of IGF1R expression, measured by H-scores incorporating staining intensity and proportion of positive tumor cells, with disease-free survival (DFS) and overall survival (OS) were evaluated in 317 and 321 patients, respectively, using Cox regression adjusting for known prognostic factors. RESULTS: Higher IGF1R expression in tumor cells was associated with worse DFS comparing highest versus lowest expression tertiles [median DFS, 10.8 vs. 16.1 months; adjusted hazard ratio (HR), 1.73; 95% confidence interval (CI), 1.24-2.44; P trend = 0.002] and worse OS (median OS, 17.4 vs. 25.8 months; HR, 1.39; 95% CI, 1.00-1.92; P trend = 0.046). The association between high IGF1R expression and reduced DFS was identified primarily among patients with a preoperative body mass index ≥25 kg/m2 (HR, 4.27; 95% CI, 2.03-8.96, comparing extreme tertiles; P interaction = 0.032). KRAS-mutant tumors had greater IGF1R expression, and IGF1R expression in tumor epithelium was inversely correlated with that in stromal cells. Mutations in IGF1R were infrequent, and no overt loss-of-function alterations were identified. Higher IGF1R expression was modestly associated with higher gene copy number (Pearson correlation coefficient = 0.26, P < 0.001). CONCLUSIONS: Higher IGF1R protein expression was associated with worse patient outcomes in resected PDAC. IMPACT: IGF1R expression in PDAC represents a potential biomarker to guide patient selection for more aggressive, multidrug regimens in the adjuvant setting.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Receptor IGF Tipo 1 / Carcinoma Ductal Pancreático Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Receptor IGF Tipo 1 / Carcinoma Ductal Pancreático Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article